J 2021

Investigator Initiated Clinical Trials (IICTs): A Systematic Search in Registries to Compare the Czech Republic and Portugal in Terms of Funding Policies and Scientific Outcomes

MADEIRA, C., Lenka HOŘAVOVÁ, F. DOS SANTOS, J. R. BATUCA, Kateřina NEBESKÁ et. al.

Základní údaje

Originální název

Investigator Initiated Clinical Trials (IICTs): A Systematic Search in Registries to Compare the Czech Republic and Portugal in Terms of Funding Policies and Scientific Outcomes

Autoři

MADEIRA, C., Lenka HOŘAVOVÁ (203 Česká republika, domácí), F. DOS SANTOS, J. R. BATUCA, Kateřina NEBESKÁ (203 Česká republika, domácí), Lenka SOUČKOVÁ (203 Česká republika, domácí), C. KUBIAK, J. DEMOTES, Regina DEMLOVÁ (203 Česká republika, domácí) a E. C. MONTEIRO (garant)

Vydání

THERAPEUTIC INNOVATION & REGULATORY SCIENCE, HEIDELBERG, SPRINGER HEIDELBERG, 2021, 2168-4790

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Německo

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 1.337

Kód RIV

RIV/00216224:14110/21:00122133

Organizační jednotka

Lékařská fakulta

UT WoS

000651680000001

Klíčová slova anglicky

Investigator initiated clinical trials; Funding; Clinical trials registry; Clinical research; Clinical trial; Clinical research outcome

Štítky

Změněno: 8. 2. 2022 09:02, Mgr. Tereza Miškechová

Anotace

V originále

Objectives Clinical trials provide one of the highest levels of evidence to support medical practice. Investigator initiated clinical trials (IICTs) answer relevant questions in clinical practice that may not be addressed by industry. For the first time, two European Countries are compared in terms of IICTs, respective funders and publications, envisaging to inspire others to use similar indicators to assess clinical research outcomes. Methods A retrospective systematic search of registered IICTs from 2004 to 2017, using four clinical trials registries was carried out in two European countries with similar population, GDP, HDI and medical schools but with different governmental models to fund clinical research. Each IICT was screened for sponsors, funders, type of intervention and associated publications, once completed. Results IICTs involving the Czech Republic and Portugal were n = 439 (42% with hospitals as sponsors) and n = 328 (47% with universities as sponsors), respectively. The Czech Republic and Portuguese funding agencies supported respectively 61 and 27 IICTs. Among these, trials with medicinal products represent 52% in Czech Republic and 4% in Portugal. In the first, a higher percentage of IICTs' publications in high impact factor journals with national investigators as authors was observed, when compared to Portugal (75% vs 15%). Conclusion The better performance in clinical research by Czech Republic might be related to the existence of specific and periodic funding for clinical research, although further data are still needed to confirm this relationship. In upcoming years, the indicators used herein might be useful to tracking clinical research outcomes in these and other European countries.

Návaznosti

CZ.02.1.01/0.0/0.0/16_013/0001826, interní kód MU
(Kód CEP: EF16_013/0001826)
Název: CZECRIN_PRO PACIENTY - zavádění inovativních moderních terapií
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CZECRIN_PRO PACIENTY - zavádění inovativních moderních terapií, PO 1 Posilování kapacit pro kvalitní výzkum
90128, velká výzkumná infrastruktura
Název: CZECRIN III